ClinicalTrials.gg
CompletedNCT02167594Updated Aug 28, 2020Results posted

Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers

A Phase 1 interventional study of Flortaucipir F18 and Brain PET scan in Progressive Supranuclear Palsy and Corticobasal Degeneration, sponsored by Avid Radiopharmaceuticals. Completed at 5 sites in United States. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-28.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in Supranuclear Palsy, Progressive with a site in United States — 19 open to participants now, 25 under way, 1 of them phase 3. Supranuclear Palsy, Progressive · United States.

Enrollment
31st of 52
29 · median 43
Started
2014
with 3 others
Phase 1
19 of 84
1 open now
Registered
21st of 84
by date

Among the 84 studies in Supranuclear Palsy, Progressive with a site in United States, this one is the 31st largest by enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2014, is one of 19 in phase 1, and was the 21st registered.

Supranuclear Palsy, Progressive

171 studies on the registry are indexed under Supranuclear Palsy, Progressive; 51 are open to participants now.

Browse Supranuclear Palsy, Progressive studies →

Open to participants now

19 of the 84 studies in Supranuclear Palsy, Progressive with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Supranuclear Palsy, Progressive studies recruiting now, 22 (58%) set no upper age limit and 2 (5%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Supranuclear Palsy, Progressive with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.

03

Conditions studied

  • Progressive Supranuclear Palsy
  • Corticobasal Degeneration
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cognitively Healthy Volunteers

  • (MMSE) ≥ 28
  • No history of cognitive decline or parkinsonian motor disorder

CBD and PSP subjects

  • Able to walk 10 steps with minimal assistance
  • MMSE ≥ 14 and ≤ 30
  • Subject has a reliable study partner who agrees to accompany subject to visits and spends at least 5 hours per week with the subject

PSP subjects only

  • Meet National Institute of Neurological Disorders and Stroke - Society for Progressive Supranuclear Palsy (NINDS-SPSP) probable or possible PSP criteria as modified for the Neuroprotection and Natural History Parkinson Plus Syndromes (NNIPPS) clinical trial

CBD subjects only

  • Meets 2013 consensus criteria for possible or probable corticobasal degeneration, corticobasal syndrome (CBS) subtype

Exclusion criteria

Exclusion Criteria:

All subjects

  • Have evidence of structural abnormalities such as vascular disease, large strokes or severe white matter disease or other mass lesion on screening MRI
  • Claustrophobia
  • Current cardiovascular disease or clinically significant abnormalities on screening (e.g. interval >450 msec)
  • Have a history of risk factors for Torsades de Pointes (e.g. heart failure, hypokalemia, family history of long QT syndrome)
  • Have a current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
  • Females of who are not surgically sterile, not refraining from sexual activity or not using reliable methods of
  • Have received or participated in a trial with medications in the past 30 days
  • Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session
  • Have a history of neuroleptic use for a prolonged period of time or within the past 6 months

PSP and CBD subjects

  • Have evidence of amyloid deposition
  • Meet National Institute on Aging-Alzheimer's Association criteria for probable Alzheimer's Disease
  • Have any other neurological condition other than CBS or PSP that could account for cognitive or motor deficits
  • Serum or plasma progranulin level less than one standard deviation below the normal subject mean for the laboratory performing the assay
  • Have a high-risk family history suggestive of tar DNA binding protein (TDP)-43 pathology or known mutations
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    PSP Subjects

    Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

  • Experimental
    CBD subjects

    Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

  • Experimental
    Healthy volunteers

    Healthy volunteers receiving a flortaucipir PET scan at baseline.

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

Interventions

  • IV injection, 370 megabecquerel (MBq) (10 mCi)

    Also known as: [F18]T807, 18F-AV-1451, LY3191748, Tauvid

  • ProcedureBrain PET scan

    positron emission tomography (PET) scan of the brain 75-105 minutes post-injection

06

What researchers measure

Primary outcomes

  1. Flortaucipir Imaging in PSP, CBD and Healthy Volunteers

    A PSP/CBD (PSP = progressive supranuclear palsy; CBD = corticobasal degeneration) targeted composite Standardized Uptake Value ratio (SUVr) was calculated as the voxel-weighted average from the regional SUVr values of the left, right, and total globus pallidus and the dentate nuclei of the cerebellum for both the baseline and 9 month PET scans. Additionally, a global cortical Alzheimer's Disease (AD)-targeted cortical SUVr was calculated. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: baseline and 9 month scans

07

Results

Posted Aug 28, 2020

Participant flow

Subjects recruited between Aug 2014 and Jul 2016.

Participant flow — Overall Study
MilestonePSP SubjectsCBD SubjectsHealthy Volunteers
Started2063
Completed1853
Not completed210
Withdrew: Withdrawal by subject200
Withdrew: Death010

Outcome measures

PrimaryFlortaucipir Imaging in PSP, CBD and Healthy Volunteers

A PSP/CBD (PSP = progressive supranuclear palsy; CBD = corticobasal degeneration) targeted composite Standardized Uptake Value ratio (SUVr) was calculated as the voxel-weighted average from the regional SUVr values of the left, right, and total globus pallidus and the dentate nuclei of the cerebellum for both the baseline and 9 month PET scans. Additionally, a global cortical Alzheimer's Disease (AD)-targeted cortical SUVr was calculated. For SUVr, a value of 1 signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
baseline and 9 month scans
Reported as:
Mean · standardized uptake value ratio (SUVr)
Flortaucipir Imaging in PSP, CBD and Healthy Volunteers
standardized uptake value ratio (SUVr)PSP SubjectsCBD SubjectsHealthy VolunteersAll Subjects
Right Dentate Baseline1.17 ± 0.121.12 ± 0.041.03 ± 0.121.15 ± 0.12
Right Dentate 9 months1.17 ± 0.111.11 ± 0.05—1.15 ± 0.10
Left Dentate Baseline1.16 ± 0.101.09 ± 0.041.08 ± 0.071.14 ± 0.09
Left Dentate 9 months1.13 ± 0.111.08 ± 0.05—1.12 ± 0.10
Right Globus Pallidus Baseline1.60 ± 0.151.40 ± 0.201.29 ± 0.061.53 ± 0.19
Right Globus Pallidus 9 Months1.58 ± 0.131.47 ± 0.19—1.55 ± 0.15
Left Globus Pallidus Baseline1.62 ± 0.151.56 ± 0.321.30 ± 0.071.58 ± 0.21
Left Globus Pallidus 9 Months1.62 ± 0.151.62 ± 0.40—1.62 ± 0.21
Global PSP/CBD Summary Baseline1.38 ± 0.101.29 ± 0.111.17 ± 0.031.34 ± 0.12
Global PSP/CBD Summary 9 Months1.37 ± 0.091.32 ± 0.13—1.36 ± 0.10
AD Cortical Baseline0.99 ± 0.030.99 ± 0.061.02 ± 0.020.99 ± 0.04
AD Cortical 9 Months0.99 ± 0.031.00 ± 0.05—0.99 ± 0.04

Adverse events

Collected over End of study for AE reporting was 48 hours after flortaucipir administration at each imaging visit.. Non-serious events are listed at a 1.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PSP Subjects0/20 (0%)0/20 (0%)2/20 (10%)
CBD Subjects1/6 (16.7%)0/6 (0%)1/6 (16.7%)
Healthy Volunteers0/3 (0%)0/3 (0%)0/3 (0%)
Most frequent other events
Most frequent other events
EventPSP SubjectsCBD SubjectsHealthy Volunteers
muscle spasmsMusculoskeletal and connective tissue disorders0/201/60/3
bronchial secretion retentionRespiratory, thoracic and mediastinal disorders1/200/60/3
astheniaGeneral disorders1/200/60/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)PSP SubjectsCBD SubjectsHealthy VolunteersTotal
Mean69.2 ± 5.8872.2 ± 7.4168.7 ± 10.4169.8 ± 6.53
Sex: Female, Male
Sex: Female, Male(Participants)PSP SubjectsCBD SubjectsHealthy VolunteersTotal
Female64010
Male142319
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PSP SubjectsCBD SubjectsHealthy VolunteersTotal
Hispanic or Latino1001
Not Hispanic or Latino196328
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PSP SubjectsCBD SubjectsHealthy VolunteersTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White186327
More than one race0000
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(Participants)PSP SubjectsCBD SubjectsHealthy VolunteersTotal
United States206329
Mini Mental Status Exam (MMSE)
Mini Mental Status Exam (MMSE)(units on a scale)PSP SubjectsCBD SubjectsHealthy VolunteersTotal
Mean26.5 ± 3.1226.3 ± 4.3229.3 ± 0.5826.7 ± 3.28
08

Study locations

5 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • UCSD Movement Disorder Clinic
    La Jolla, California 92037, United States
  • UCSF Neurosciences Clinical Research Unit
    San Francisco, California 94158, United States
  • Molecular Neuroimaging
    New Haven, Connecticut 06510, United States
  • Perelman School of Medicine
    Philadelphia, Pennsylvania 19104, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Jul 2016, 22 months.

Results were first posted in Aug 2020, 4 years 1 month after primary completion.

Of 15 phase 1 interventional studies under Supranuclear Palsy, Progressive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 23. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2014
First posted
Jun 19, 2014
StartActual
Aug 12, 2014
Primary completionActual
Jul 11, 2016
CompletionActual
Jul 11, 2016
Results first posted
Aug 28, 2020
Last update
Aug 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02167594
Responsible party
Sponsor
First posted
Jun 19, 2014
Start date
Aug 12, 2014
Primary completion
Jul 11, 2016
Completion
Jul 11, 2016
Results posted
Aug 28, 2020
Last update
Aug 28, 2020

Study contacts

Medical Director
study director · Avid Radiopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion